Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
暂无分享,去创建一个
K. Rahbar | B. Tombal | A. Schmall | D. George | J. O’Sullivan | K. Fizazi | R. McKay | N. Shore | P. Sandström | F. Verholen | Anja Schmall
[1] G. Treglia,et al. Bone Scintigraphy versus PSMA-Targeted PET/CT or PET/MRI in Prostate Cancer: Lessons Learned from Recent Systematic Reviews and Meta-Analyses , 2022, Cancers.
[2] P. Stattin,et al. Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden. , 2022, Clinical genitourinary cancer.
[3] L. Azoulay. Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective , 2022, The oncologist.
[4] K. Rahbar,et al. Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study. , 2022, Journal of Clinical Oncology.
[5] N. Vogelzang,et al. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis. , 2022, Clinical genitourinary cancer.
[6] M. Sydes,et al. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. , 2022, European urology.
[7] F. Saad,et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. , 2022, The New England journal of medicine.
[8] N. Agarwal,et al. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study) , 2022, Prostate cancer and prostatic diseases.
[9] F. Saad,et al. A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. , 2022, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[10] F. Chun,et al. Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride , 2022, Cancers.
[11] J. Sylvester,et al. 177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience , 2021, The Journal of Nuclear Medicine.
[12] K. Broich,et al. Real‐World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value , 2021, Clinical pharmacology and therapeutics.
[13] C. Quinten,et al. Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence? , 2021, Clinical pharmacology and therapeutics.
[14] R. Ionescu-Ittu,et al. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors , 2021, Advances in Therapy.
[15] C. Catton,et al. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223 , 2021, Cancer medicine.
[16] K. Rahbar,et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.
[17] E. Basch,et al. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer , 2021, PloS one.
[18] F. Saad,et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. , 2021 .
[19] K. Fizazi,et al. Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study. , 2021 .
[20] J. Weiss,et al. Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings , 2021, The Prostate.
[21] M. Terris,et al. Safety of concomitant therapy with radium‐223 and abiraterone or enzalutamide in a real‐world population , 2021, The Prostate.
[22] S. Nilsson,et al. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223 , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[23] M. Nozawa,et al. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer , 2021, World Journal of Urology.
[24] N. Bander,et al. Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer , 2021, Frontiers in Oncology.
[25] V. Lowe,et al. Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. , 2021, Clinical genitourinary cancer.
[26] D. Gillett,et al. Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases , 2020, World journal of nuclear medicine.
[27] F. Sundram,et al. Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway. , 2020, Nuclear medicine communications.
[28] P. Goebell,et al. Insights into Treatment Patterns in the Routine Care of Patients Diagnosed with Metastatic Castration-Resistant Prostate Cancer in Germany After the Introduction of New Therapies , 2020 .
[29] F. Saad,et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[30] M. Taplin,et al. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center , 2020, Prostate Cancer and Prostatic Diseases.
[31] L. Cindolo,et al. Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with 223Radium-dichloride: a national multicenter study , 2020, Annals of Nuclear Medicine.
[32] C. Parker,et al. Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] K. Aben,et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. , 2020, Future oncology.
[34] I. Pedley,et al. Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).
[35] F. Saad,et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer , 2020, Prostate Cancer and Prostatic Diseases.
[36] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[37] S. Fanti,et al. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223 , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[38] F. Saad,et al. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. , 2020, Clinical genitourinary cancer.
[39] J. Carles,et al. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. , 2020, European urology oncology.
[40] L. Edenbrandt,et al. Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients , 2019, The Journal of Nuclear Medicine.
[41] W. Zwart,et al. A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population , 2019, International journal of cancer.
[42] L. Collette,et al. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. , 2019, JAMA oncology.
[43] Liying Zhang,et al. Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome , 2019, Cancer management and research.
[44] H. Gelderblom,et al. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. , 2019, Clinical genitourinary cancer.
[45] N. Agarwal,et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.
[46] F. Saad,et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[47] F. Alongi,et al. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration‐resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region , 2019, Clinical genitourinary cancer.
[48] S. Dizdarevic,et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[49] W. Oyen,et al. Consensus on molecular imaging and theranostics in prostate cancer. , 2018, The Lancet. Oncology.
[50] Kamlesh Khunti,et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.
[51] P. Hoskin,et al. Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity , 2018, AntiCancer Research.
[52] D. Bottomley,et al. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).
[53] J. Mortensen,et al. 223Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity , 2017, The Journal of Nuclear Medicine.
[54] A. Farcomeni,et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride , 2018, Annals of Nuclear Medicine.
[55] J Bogaerts,et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] S. Fosså,et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. , 2017, European urology.
[57] G. Flux. Imaging and dosimetry for radium-223: the potential for personalized treatment , 2017, The British journal of radiology.
[58] W. Oyen,et al. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[59] C. Parker,et al. The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[60] O. Sartor,et al. Radium‐223 Use in Clinical Practice and Variables Associated With Completion of Therapy , 2017, Clinical genitourinary cancer.
[61] R. Fimmers,et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. , 2017, Oncotarget.
[62] R. Califf,et al. Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.
[63] M. Wirth,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[64] Ronald C. Chen,et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[66] L. Raymond,et al. Abiraterone in metastatic prostate cancer. , 2013, The New England journal of medicine.
[67] Thomas Wiegel,et al. Guidelines on Prostate Cancer , 2013 .
[68] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[69] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[70] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[71] A. Horwich,et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] H. Moch,et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.
[73] Wellbutrin,et al. Prescribing Information , 2015, European journal of haematology.
[74] R. Navinchandra Amin,et al. Real World Analysis , 1988 .
[75] K. Shadan,et al. Available online: , 2012 .